Alejandra Carreira
@ascarreira.bsky.social
Marketing specialist & former molecular biologist. I design and execute marketing strategies for Life Science and Biotech companies.
Find me on LinkedIn
Find me on LinkedIn
Gene therapy to rebuild the immune system?
This study reports a phase 1–2 clinical trial evaluating 10 children with newly diagnosed ART-SCID who received a new lentiviral gene therapy.
ART-SCID patients show defects in T cell development and function. They were dosed:
This study reports a phase 1–2 clinical trial evaluating 10 children with newly diagnosed ART-SCID who received a new lentiviral gene therapy.
ART-SCID patients show defects in T cell development and function. They were dosed:
December 24, 2025 at 4:08 PM
Gene therapy to rebuild the immune system?
This study reports a phase 1–2 clinical trial evaluating 10 children with newly diagnosed ART-SCID who received a new lentiviral gene therapy.
ART-SCID patients show defects in T cell development and function. They were dosed:
This study reports a phase 1–2 clinical trial evaluating 10 children with newly diagnosed ART-SCID who received a new lentiviral gene therapy.
ART-SCID patients show defects in T cell development and function. They were dosed:
Titles are dead.
Whether you are writing a blog section or a LinkedIn post, don’t start with “Introduction” or “Why it matters”.
Attention span has dropped to 0.1 seconds.
Start with conclusions.
People want efficient reading today more than ever.
Whether you are writing a blog section or a LinkedIn post, don’t start with “Introduction” or “Why it matters”.
Attention span has dropped to 0.1 seconds.
Start with conclusions.
People want efficient reading today more than ever.
December 23, 2025 at 4:08 PM
Titles are dead.
Whether you are writing a blog section or a LinkedIn post, don’t start with “Introduction” or “Why it matters”.
Attention span has dropped to 0.1 seconds.
Start with conclusions.
People want efficient reading today more than ever.
Whether you are writing a blog section or a LinkedIn post, don’t start with “Introduction” or “Why it matters”.
Attention span has dropped to 0.1 seconds.
Start with conclusions.
People want efficient reading today more than ever.
You are not good, you are better.
Convince your audience that you are the best choice on the market for their needs
#lifescience #lifesciencemarketing #genetherapy #geneediting
Convince your audience that you are the best choice on the market for their needs
#lifescience #lifesciencemarketing #genetherapy #geneediting
December 17, 2025 at 4:08 PM
You are not good, you are better.
Convince your audience that you are the best choice on the market for their needs
#lifescience #lifesciencemarketing #genetherapy #geneediting
Convince your audience that you are the best choice on the market for their needs
#lifescience #lifesciencemarketing #genetherapy #geneediting
Nobody ever said:
"Oh man, I'm really looking for a state-of-art technology for my cell culture"
What I have heard:
"I need something for my cells to stop dying"
That's why numbers and benefits need to appear in your headlines.
"Oh man, I'm really looking for a state-of-art technology for my cell culture"
What I have heard:
"I need something for my cells to stop dying"
That's why numbers and benefits need to appear in your headlines.
December 16, 2025 at 4:04 PM
Nobody ever said:
"Oh man, I'm really looking for a state-of-art technology for my cell culture"
What I have heard:
"I need something for my cells to stop dying"
That's why numbers and benefits need to appear in your headlines.
"Oh man, I'm really looking for a state-of-art technology for my cell culture"
What I have heard:
"I need something for my cells to stop dying"
That's why numbers and benefits need to appear in your headlines.
2D cell lines cannot reflect patient variability, and mouse models often fail on being a reliable translational model
Vlachogiannis et al., built a living biobank of patient-derived organoids (PDOs) from heavily pretreated cancer patients enrolled in phase I/II trials.
And they very accurate🧵🪡
Vlachogiannis et al., built a living biobank of patient-derived organoids (PDOs) from heavily pretreated cancer patients enrolled in phase I/II trials.
And they very accurate🧵🪡
November 19, 2025 at 4:06 PM
2D cell lines cannot reflect patient variability, and mouse models often fail on being a reliable translational model
Vlachogiannis et al., built a living biobank of patient-derived organoids (PDOs) from heavily pretreated cancer patients enrolled in phase I/II trials.
And they very accurate🧵🪡
Vlachogiannis et al., built a living biobank of patient-derived organoids (PDOs) from heavily pretreated cancer patients enrolled in phase I/II trials.
And they very accurate🧵🪡
From where does a CRO actually get its clients?
In biotech, every purchase carries risk (delays, rework, lost data...) and teams rarely pick suppliers or partners from ads alone.
The number 1 source of leads is referrals.
But if that's mostly customer service, how can marketing help? ⬇️⬇️
In biotech, every purchase carries risk (delays, rework, lost data...) and teams rarely pick suppliers or partners from ads alone.
The number 1 source of leads is referrals.
But if that's mostly customer service, how can marketing help? ⬇️⬇️
November 13, 2025 at 7:20 AM
From where does a CRO actually get its clients?
In biotech, every purchase carries risk (delays, rework, lost data...) and teams rarely pick suppliers or partners from ads alone.
The number 1 source of leads is referrals.
But if that's mostly customer service, how can marketing help? ⬇️⬇️
In biotech, every purchase carries risk (delays, rework, lost data...) and teams rarely pick suppliers or partners from ads alone.
The number 1 source of leads is referrals.
But if that's mostly customer service, how can marketing help? ⬇️⬇️
A CRO might say:
“We deliver reports in 5 days.”
But if accuracy is the client’s top concern, that sounds rushed, not reliable.
List speed only when time is the bottleneck.
“We deliver reports in 5 days.”
But if accuracy is the client’s top concern, that sounds rushed, not reliable.
List speed only when time is the bottleneck.
November 10, 2025 at 7:30 AM
A CRO might say:
“We deliver reports in 5 days.”
But if accuracy is the client’s top concern, that sounds rushed, not reliable.
List speed only when time is the bottleneck.
“We deliver reports in 5 days.”
But if accuracy is the client’s top concern, that sounds rushed, not reliable.
List speed only when time is the bottleneck.
How I write a case study when the company doesn't have any clients yet.
I explain the full process on this article: ascarreira.com/how-to-write...
I explain the full process on this article: ascarreira.com/how-to-write...
November 5, 2025 at 7:12 AM
How I write a case study when the company doesn't have any clients yet.
I explain the full process on this article: ascarreira.com/how-to-write...
I explain the full process on this article: ascarreira.com/how-to-write...
An ad says: “We’re experts.”
A case study proves it.
A white paper shows why it matters.
The goal: move readers closer to believing you're the right choice.
A case study proves it.
A white paper shows why it matters.
The goal: move readers closer to believing you're the right choice.
November 4, 2025 at 7:10 AM
An ad says: “We’re experts.”
A case study proves it.
A white paper shows why it matters.
The goal: move readers closer to believing you're the right choice.
A case study proves it.
A white paper shows why it matters.
The goal: move readers closer to believing you're the right choice.
High-throughput, State-of-the-art, Cutting-edge...
Been there, done that.
But now it's time to move on.
Next time try numbers over adjectives:
"Get results 2× faster than with standard LC-MS.”
Been there, done that.
But now it's time to move on.
Next time try numbers over adjectives:
"Get results 2× faster than with standard LC-MS.”
November 3, 2025 at 7:10 AM
High-throughput, State-of-the-art, Cutting-edge...
Been there, done that.
But now it's time to move on.
Next time try numbers over adjectives:
"Get results 2× faster than with standard LC-MS.”
Been there, done that.
But now it's time to move on.
Next time try numbers over adjectives:
"Get results 2× faster than with standard LC-MS.”
How many times have you heard that ads are a waste of money?
👉🏻 Read Why Content Marketing is the New Advertising for Biotech:
ascarreira.com/why-content-...
👉🏻 Read Why Content Marketing is the New Advertising for Biotech:
ascarreira.com/why-content-...
October 30, 2025 at 7:10 AM
How many times have you heard that ads are a waste of money?
👉🏻 Read Why Content Marketing is the New Advertising for Biotech:
ascarreira.com/why-content-...
👉🏻 Read Why Content Marketing is the New Advertising for Biotech:
ascarreira.com/why-content-...
3 tricks to make content when you don't have a marketing team
- Write blog posts. Each subheading can become a LinkedIn post.
- Don’t try to explain every single detail of a product or project in a single post.
- Focus on one idea, benefit or application per post.
Follow for more
- Write blog posts. Each subheading can become a LinkedIn post.
- Don’t try to explain every single detail of a product or project in a single post.
- Focus on one idea, benefit or application per post.
Follow for more
October 29, 2025 at 7:23 AM
3 tricks to make content when you don't have a marketing team
- Write blog posts. Each subheading can become a LinkedIn post.
- Don’t try to explain every single detail of a product or project in a single post.
- Focus on one idea, benefit or application per post.
Follow for more
- Write blog posts. Each subheading can become a LinkedIn post.
- Don’t try to explain every single detail of a product or project in a single post.
- Focus on one idea, benefit or application per post.
Follow for more
When writing copy, start by asking yourself:
“How does this help my customer?”
Then build it backwards.
You’re not selling “a reliable workflow.”
You’re selling confidence when meeting the FDA.
“How does this help my customer?”
Then build it backwards.
You’re not selling “a reliable workflow.”
You’re selling confidence when meeting the FDA.
October 28, 2025 at 7:00 AM
When writing copy, start by asking yourself:
“How does this help my customer?”
Then build it backwards.
You’re not selling “a reliable workflow.”
You’re selling confidence when meeting the FDA.
“How does this help my customer?”
Then build it backwards.
You’re not selling “a reliable workflow.”
You’re selling confidence when meeting the FDA.
Everyone says “reliable data.”
But in science, proof is the best adjective.
Try:
“<2% CV across replicates.”
“99.8% recovery rate for small molecules.”
But in science, proof is the best adjective.
Try:
“<2% CV across replicates.”
“99.8% recovery rate for small molecules.”
October 27, 2025 at 7:00 AM
Everyone says “reliable data.”
But in science, proof is the best adjective.
Try:
“<2% CV across replicates.”
“99.8% recovery rate for small molecules.”
But in science, proof is the best adjective.
Try:
“<2% CV across replicates.”
“99.8% recovery rate for small molecules.”
Top 6 things that shocked me when researching in gene editing #WorldCRISPRDay
- Sometimes editing efficiency can be as low as 5%, yet you will still see a change in phenotype.
- The genome is truly strong and delicate at the same time.
- Chromatin folding can make or break your target.
- Sometimes editing efficiency can be as low as 5%, yet you will still see a change in phenotype.
- The genome is truly strong and delicate at the same time.
- Chromatin folding can make or break your target.
October 23, 2025 at 6:22 AM
Top 6 things that shocked me when researching in gene editing #WorldCRISPRDay
- Sometimes editing efficiency can be as low as 5%, yet you will still see a change in phenotype.
- The genome is truly strong and delicate at the same time.
- Chromatin folding can make or break your target.
- Sometimes editing efficiency can be as low as 5%, yet you will still see a change in phenotype.
- The genome is truly strong and delicate at the same time.
- Chromatin folding can make or break your target.
Instead of
“Automate your data processing pipeline”
Say
“Turn a week of data analysis into a one-hour workflow.”
Scientists don’t buy automation.
They buy time.
“Automate your data processing pipeline”
Say
“Turn a week of data analysis into a one-hour workflow.”
Scientists don’t buy automation.
They buy time.
October 22, 2025 at 6:10 AM
Instead of
“Automate your data processing pipeline”
Say
“Turn a week of data analysis into a one-hour workflow.”
Scientists don’t buy automation.
They buy time.
“Automate your data processing pipeline”
Say
“Turn a week of data analysis into a one-hour workflow.”
Scientists don’t buy automation.
They buy time.
Your goal isn’t to make readers think.
It’s to make them understand instantly.
A good headline:
“Next-gen delivery platform for RNA vaccines.”
A great one:
“Deliver your mRNA vaccine with 95% efficiency.”
It’s to make them understand instantly.
A good headline:
“Next-gen delivery platform for RNA vaccines.”
A great one:
“Deliver your mRNA vaccine with 95% efficiency.”
October 20, 2025 at 7:05 AM
Your goal isn’t to make readers think.
It’s to make them understand instantly.
A good headline:
“Next-gen delivery platform for RNA vaccines.”
A great one:
“Deliver your mRNA vaccine with 95% efficiency.”
It’s to make them understand instantly.
A good headline:
“Next-gen delivery platform for RNA vaccines.”
A great one:
“Deliver your mRNA vaccine with 95% efficiency.”
Advertising → great for reaching a broad audience.
Content marketing → great to convince your audience.
📥 Join my newsletter to receive tips on digital marketing and copywriting: ascarreira.com/newsletter/?...
Content marketing → great to convince your audience.
📥 Join my newsletter to receive tips on digital marketing and copywriting: ascarreira.com/newsletter/?...
October 17, 2025 at 6:02 AM
Advertising → great for reaching a broad audience.
Content marketing → great to convince your audience.
📥 Join my newsletter to receive tips on digital marketing and copywriting: ascarreira.com/newsletter/?...
Content marketing → great to convince your audience.
📥 Join my newsletter to receive tips on digital marketing and copywriting: ascarreira.com/newsletter/?...
If I had only one hour this week to spend on marketing, I would have no doubt where to put it: on writing a case study.
🔗 Read "How to write a case study without draining your technical team" in my blog: ascarreira.com/how-to-write...
🔗 Read "How to write a case study without draining your technical team" in my blog: ascarreira.com/how-to-write...
October 16, 2025 at 6:10 AM
If I had only one hour this week to spend on marketing, I would have no doubt where to put it: on writing a case study.
🔗 Read "How to write a case study without draining your technical team" in my blog: ascarreira.com/how-to-write...
🔗 Read "How to write a case study without draining your technical team" in my blog: ascarreira.com/how-to-write...
Marketing is context.
Even the right message fails in the wrong moment.
A CRO might say:
“We deliver reports in 5 days.”
But if accuracy is the client’s top concern,
that sounds rushed, not reliable.
List speed only when time is the bottleneck.
Even the right message fails in the wrong moment.
A CRO might say:
“We deliver reports in 5 days.”
But if accuracy is the client’s top concern,
that sounds rushed, not reliable.
List speed only when time is the bottleneck.
October 15, 2025 at 6:02 AM
Marketing is context.
Even the right message fails in the wrong moment.
A CRO might say:
“We deliver reports in 5 days.”
But if accuracy is the client’s top concern,
that sounds rushed, not reliable.
List speed only when time is the bottleneck.
Even the right message fails in the wrong moment.
A CRO might say:
“We deliver reports in 5 days.”
But if accuracy is the client’s top concern,
that sounds rushed, not reliable.
List speed only when time is the bottleneck.
Ads stop working when your budget runs out.
But content is different, they can generate leads long after being published
🔗 Read more on my new blog post: ascarreira.com/why-content-...
But content is different, they can generate leads long after being published
🔗 Read more on my new blog post: ascarreira.com/why-content-...
October 14, 2025 at 12:26 PM
Ads stop working when your budget runs out.
But content is different, they can generate leads long after being published
🔗 Read more on my new blog post: ascarreira.com/why-content-...
But content is different, they can generate leads long after being published
🔗 Read more on my new blog post: ascarreira.com/why-content-...
I see many young companies going all-in on social media.
They post daily, chase visibility, and measure likes.
But the problem with social media is that posts are temporary
People will only find it on their feeds for a few days (1-2 weeks, if you're lucky).
However.. a web page is permanent.
They post daily, chase visibility, and measure likes.
But the problem with social media is that posts are temporary
People will only find it on their feeds for a few days (1-2 weeks, if you're lucky).
However.. a web page is permanent.
October 14, 2025 at 6:46 AM
I see many young companies going all-in on social media.
They post daily, chase visibility, and measure likes.
But the problem with social media is that posts are temporary
People will only find it on their feeds for a few days (1-2 weeks, if you're lucky).
However.. a web page is permanent.
They post daily, chase visibility, and measure likes.
But the problem with social media is that posts are temporary
People will only find it on their feeds for a few days (1-2 weeks, if you're lucky).
However.. a web page is permanent.
A few years ago, I was working on a miRNA project to inhibit an appetite pathway in the brain.
I remember having a lot of doubts about what was possible:
“Can I measure functional activity in this specific brain region?”
“Is there a protocol to quantify miRNA-mRNA?”
I remember having a lot of doubts about what was possible:
“Can I measure functional activity in this specific brain region?”
“Is there a protocol to quantify miRNA-mRNA?”
October 9, 2025 at 12:32 PM
A few years ago, I was working on a miRNA project to inhibit an appetite pathway in the brain.
I remember having a lot of doubts about what was possible:
“Can I measure functional activity in this specific brain region?”
“Is there a protocol to quantify miRNA-mRNA?”
I remember having a lot of doubts about what was possible:
“Can I measure functional activity in this specific brain region?”
“Is there a protocol to quantify miRNA-mRNA?”
A lab looking for device X is not looking for the fastest device on the market.
They're looking for solutions.
If time is an issue for them,
That’s when you should list speed as a benefit.
They're looking for solutions.
If time is an issue for them,
That’s when you should list speed as a benefit.
October 8, 2025 at 7:25 AM
A lab looking for device X is not looking for the fastest device on the market.
They're looking for solutions.
If time is an issue for them,
That’s when you should list speed as a benefit.
They're looking for solutions.
If time is an issue for them,
That’s when you should list speed as a benefit.
Making content isn’t expensive.
Making content that nobody reads is.
The real cost of marketing is measured in ROI, not in your team’s salary.
Making content that nobody reads is.
The real cost of marketing is measured in ROI, not in your team’s salary.
October 2, 2025 at 1:43 PM
Making content isn’t expensive.
Making content that nobody reads is.
The real cost of marketing is measured in ROI, not in your team’s salary.
Making content that nobody reads is.
The real cost of marketing is measured in ROI, not in your team’s salary.